ABSTRACT
The objective was to evaluate the applicability and reliability of an unbiased stereological computerised tomography (CT) method for estimating total human body (HB), skeletal muscle (SM) and adipose tissue (AT) volumes in groups of neuromuscular patients. In 10 neuromuscular patients HB, SM and AT volumes were estimated using systematic sampling on equidistant CT sections throughout the total body axis using a counting grid with systematically ordered intersection points. Each intersection point hitting HB, SM or AT represented a known volume dependent on intersection point distance and sum of section thickness and gap. Random and systematic intra- and interobserver errors for volume estimates were below 0.035. These errors were negligible to the coefficient of variation of the group mean, being 0.190 for HB, 0.323 for SM and 0.471 for AT. Even in the presence of intrafascicular and intramuscular fat in neuromuscular patients, unbiased and reliable quantification of HB, SM and AT is possible.
Subject(s)
Adipose Tissue/pathology , Muscle, Skeletal/pathology , Neuromuscular Diseases/pathology , Tomography Scanners, X-Ray Computed , Adult , Female , Human Body , Humans , Male , Middle Aged , Reproducibility of Results , Sensitivity and SpecificitySubject(s)
Carotid Artery, Internal , Cerebral Hemorrhage/prevention & control , Endarterectomy, Carotid/adverse effects , Monitoring, Intraoperative , Ultrasonography, Doppler, Transcranial , Blood Flow Velocity , Carotid Artery, Internal/diagnostic imaging , Carotid Stenosis/surgery , Cerebral Hemorrhage/etiology , Humans , Middle Cerebral Artery/diagnostic imaging , Middle Cerebral Artery/physiology , Pulsatile Flow , Regional Blood FlowABSTRACT
BACKGROUND: In animals and healthy volunteers beta2-adrenergic agonists increase muscle strength and mass, in particular when combined with strength training. In patients with facioscapulohumeral muscular dystrophy (FSHD) albuterol may exert anabolic effects. The authors evaluated the effect of strength training and albuterol on muscle strength and volume in FSHD. METHODS: Sixty-five patients were randomized to strength training of elbow flexors and ankle dorsiflexors or non-training. After 26 weeks albuterol (sustained-release, 8 mg BID) was added in a randomized, double-blind, placebo-controlled design. Primary outcome was maximum voluntary isometric strength (MVIC) at 52 weeks. Secondary outcomes comprised dynamic strength and muscle volume. RESULTS: Training and albuterol were well tolerated. Training of elbow flexors did not result in a significant effect on MVIC, but dynamic strength improved significantly. Elbow flexor MVIC strength increased significantly in albuterol vs placebo treated patients. Ankle dorsiflexor strength decreased in all groups. Eleven out of twelve non-trained muscles in the albuterol group showed a positive effect on MVIC compared to the placebo group (p < 0.05 in seven muscle groups). Muscle volume decreased in the placebo-treated, and increased in the albuterol-treated patients. No synergistic or antagonistic effects were observed between training and albuterol. CONCLUSIONS: In FSHD strength training and albuterol appear safe interventions with limited positive effect on muscle strength and volume. Consequences of prolonged use are presently unclear, which precludes routine prescription.
Subject(s)
Adrenergic beta-Agonists/therapeutic use , Albuterol/therapeutic use , Muscular Dystrophy, Facioscapulohumeral/therapy , Weight Lifting , Adrenergic beta-Agonists/administration & dosage , Adult , Albuterol/administration & dosage , Ankle Joint , Combined Modality Therapy , Delayed-Action Preparations , Double-Blind Method , Elbow Joint , Female , Humans , Male , Middle Aged , Muscular Dystrophy, Facioscapulohumeral/drug therapy , Physical Endurance , Respiratory Function Tests , Treatment OutcomeABSTRACT
Nemaline myopathy is a congenital neuromuscular disorder characterized by muscle weakness and the presence of nemaline rods. Five genes have now been associated with nemaline myopathy: alpha-tropomyosin-3 (TPM3), alpha-actin (ACTA1), nebulin (NEB), beta-tropomysin (TPM2) and troponin T (TNNT1). In addition, mutations in the ryanodine receptor gene (RYR1) have been associated with core-rod myopathy. Here we report linkage in two unrelated families, with a variant of nemaline myopathy, with associated core-like lesions. The clinical phenotype consists of muscle weakness in addition to a peculiar kind of muscle slowness. A genome-wide scan revealed a locus for nemaline myopathy with core-like lesions on chromosome 15q21-q23 for both families. Combining the two families gave a two-point LOD score of 10.65 for D15S993. The alpha-tropomyosin-1 gene (TPM1) located within this region is the strongest candidate gene. However, no mutations were found in the protein-coding region of TPM1, although small deletions or mutations in an intron cannot be excluded. The critical region contains few other candidate genes coding for muscle proteins and several genes of unknown function, and has not yet been sequenced completely. The novel phenotype of nemaline myopathy in the two presented families corresponds to an also novel, as yet uncharacterized, genotype.
Subject(s)
Chromosomes, Human, Pair 15/genetics , Myopathies, Nemaline/genetics , Adolescent , Adult , Female , Genetic Linkage , Genotype , Haplotypes , Humans , Lod Score , Male , Microsatellite Repeats , Muscle, Skeletal/pathology , Myopathies, Nemaline/pathology , Pedigree , Phenotype , Tropomyosin/geneticsABSTRACT
We present a five-generation family with a novel phenotype of autosomal dominant nemaline myopathy not linked to the three genes known to be causative for nemaline myopathy (alpha-tropomyosin-3, nebulin, and alpha-actin). Although there was muscle weakness in the neck flexors and proximal muscles of the limbs, as found in other families, facial, ankle dorsiflexor and respiratory muscles were normal. The most remarkable clinical feature was a peculiar kind of slowness in movement not reported previously in nemaline myopathy.
